1899: Charles E. Frosst Canada & Co. is founded. From the start, Charles E. Frosst and his four associates made it clear that their company was an innovator, rapidly introducing new products such as the famous numbered analgesics known as 217® and 222®.
1926: Schering-Plough Canada is founded, two years before Schering Corporation. At that time, the company had established its first headquarters in Montréal's Victoria Square. It was then selling pharmaceutical products from its parent company, Schering AG, based in Germany
1940s: Charles E. Frosst Canada pioneered nuclear medicine in Canada by developing the country's first radioactive pharmaceutical products, for sale here and abroad. In 1940, Schering-Plough Canada moved to new facilities on St. Pierre Street, in Montréal, where it began manufacturing operations. In 1943, the ownership changed hands and the company became Schering Corporation Limited (later Schering-Plough Canada), a subsidiary of Schering Corporation U. S. A.
1953: Schering-Plough Canada moves to Labarre Street, in Ville St. Laurent. It had a staff of about 100 at the time.
1961: Schering-Plough moves with a staff of 147 to a new site on the Trans-Canada Highway. At the new location, the company was able to integrate manufacturing and distribution activities on a larger scale.
1965: Charles E. Frosst Canada & Co. joined another, even more venerable pharmaceutical dynasty, Merck & Co., Inc. of New Jersey.
1968: Merck Frosst Laboratories was created to act as the service company to the two sales companies: Merck Sharp & Dohme Canada Limited and Charles E. Frosst & Co.
1979: Scientists at the Merck Frosst Centre for Therapeutic Research start investigating leukotrienes in 1979. This line of research led to the development of SINGULAIR® (montelukast sodium), an oral asthma medication that adults and children as young as two can take daily to control their asthma symptoms.
1982: Merck Frosst Canada Inc. becomes a fully-integrated pharmaceutical company. The company later changed its name to Merck Frosst Canada Ltd. and, more recently, to Merck Canada Inc.
2002: Schering-Plough's Consumer Healthcare Division is integrated. In doing so, several product lines were added to the portfolio, including Coppertone®, Solarcaine®, Dr.Scholl's® and Muskol®.
2009: Merck and Schering-Plough combine to create the world's second-largest pharmaceutical company by market share.
2010: While announcing the closure of the Centre for Therapeutic Research in July 2010, Merck Canada committed to keep a strong presence in the life sciences and innovation sector in Québec and Canada by investing an incremental $100 million over the next five years in research and development with companies and academic institutions in Québec.